Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12077902 | 1.00 | PARP11 (0.44) | PARP11PARP10GSK3BGRM5CDC7 | |
| SCHEMBL30720809 | 0.92 | PARP10 (0.54) | PARP11PARP10GRM5PARP1PDPK1 | |
| SCHEMBL1636716 | 0.92 | PARP10 (0.54) | PARP11PARP10GRM5PARP1PDPK1 | |
| SCHEMBL12078239 | 0.84 | PARP10 (0.38) | PARP11PARP10GRM5BACE1PARP1 | |
| SCHEMBL274197 | 0.83 | ROCK1 (0.43) | GSK3BGRM5LPLLIPG | |
| SCHEMBL2052209 | 0.81 | PARP10 (0.54) | PARP11PARP10BACE1PARP1PDPK1 | |
| SCHEMBL29676875 | 0.81 | PARP10 (0.54) | PARP11PARP10BACE1PARP1PDPK1 | |
| SCHEMBL21382549 | 0.81 | KDM4E (0.43) | LPLLIPG | |
| SCHEMBL29984001 | 0.81 | MAOB (0.47) | GRM5LPLLIPG | |
| SCHEMBL27080470 | 0.81 | MAOB (0.47) | GRM5LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | PARP11 1176/4885PARP10 2072/4885GSK3B 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.